CA2002182A1 - Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi - Google Patents

Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi

Info

Publication number: CA2002182A1
Authority: CA; Canada
Prior art keywords: methods; compositions; premenstrual; treating; luteal phase
Prior art date: 1989-11-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA 2002182

Other languages

English (en)

Other versions

CA2002182C (fr

Inventor

Richard J. Wurtman

Judith J. Wurtman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Massachusetts Institute of Technology

Original Assignee

Massachusetts Institute of Technology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-03

Filing date

1989-11-03

Publication date

1991-05-03

1989-11-03 Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology

1989-11-03 Priority to CA 2002182 priority Critical patent/CA2002182C/fr

1991-05-03 Publication of CA2002182A1 publication Critical patent/CA2002182A1/fr

2000-06-13 Application granted granted Critical

2000-06-13 Publication of CA2002182C publication Critical patent/CA2002182C/fr

2009-11-03 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title abstract 3
230000029849 luteinization Effects 0.000 title 1
208000011580 syndromic disease Diseases 0.000 title 1
DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 abstract 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 abstract 1
206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
230000036528 appetite Effects 0.000 abstract 1
235000019789 appetite Nutrition 0.000 abstract 1
229960004597 dexfenfluramine Drugs 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229960002464 fluoxetine Drugs 0.000 abstract 1
230000036651 mood Effects 0.000 abstract 1
230000002295 serotoninergic effect Effects 0.000 abstract 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 2002182 1989-11-03 1989-11-03 Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi Expired - Fee Related CA2002182C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2002182 CA2002182C (fr)	1989-11-03	1989-11-03	Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2002182 CA2002182C (fr)	1989-11-03	1989-11-03	Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi

Publications (2)

Publication Number	Publication Date
CA2002182A1 true CA2002182A1 (fr)	1991-05-03
CA2002182C CA2002182C (fr)	2000-06-13

Family

ID=4143458

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2002182 Expired - Fee Related CA2002182C (fr)	1989-11-03	1989-11-03	Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi

Country Status (1)

Country	Link
CA (1)	CA2002182C (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006108591A1 (fr)	2005-04-11	2006-10-19	Novartis Ag	1h-quinaz0line-2,4-diones et leur utilisation en tant que ligands du recepteur ampa
EP2336129A1 (fr)	2004-06-18	2011-06-22	Novartis AG	1-aza-bicyclo[3.3.1]nonanes
EP2354141A1 (fr)	2005-12-16	2011-08-10	Novartis AG	(1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines en tant que ligands cholinergiques du n-achr pour le traitement de troubles psychotiques et neurodegeneatifs
EP2361914A1 (fr)	2005-12-16	2011-08-31	Novartis AG	[(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes comme ligands cholinergiques de n-achr pour le traitement des troubles psychotiques et neurodegeneratifs.
EP2457911A1 (fr)	2004-07-14	2012-05-30	Novartis AG	Dérivés de 3-(hétéroaryl-oxy)-2-alkyl-1-aza-bicycloalkyle en tant que ligands nAChR alpha7 pour le traitement des maladies du SNC

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0220581D0 (en)	2002-09-04	2002-10-09	Novartis Ag	Organic Compound

1989
- 1989-11-03 CA CA 2002182 patent/CA2002182C/fr not_active Expired - Fee Related

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2336129A1 (fr)	2004-06-18	2011-06-22	Novartis AG	1-aza-bicyclo[3.3.1]nonanes
EP2457911A1 (fr)	2004-07-14	2012-05-30	Novartis AG	Dérivés de 3-(hétéroaryl-oxy)-2-alkyl-1-aza-bicycloalkyle en tant que ligands nAChR alpha7 pour le traitement des maladies du SNC
WO2006108591A1 (fr)	2005-04-11	2006-10-19	Novartis Ag	1h-quinaz0line-2,4-diones et leur utilisation en tant que ligands du recepteur ampa
EP2463278A1 (fr)	2005-04-11	2012-06-13	Novartis AG	1h-quinaz0line-2,4-diones et leur utilisation en tant que ligands du recepteur ampa
EP2468732A1 (fr)	2005-04-11	2012-06-27	Novartis AG	1H-quinazoline-2,4-diones
EP2476671A1 (fr)	2005-04-11	2012-07-18	Novartis AG	1H-quinazoline-2,4-diones
EP2354141A1 (fr)	2005-12-16	2011-08-10	Novartis AG	(1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines en tant que ligands cholinergiques du n-achr pour le traitement de troubles psychotiques et neurodegeneatifs
EP2361914A1 (fr)	2005-12-16	2011-08-31	Novartis AG	[(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes comme ligands cholinergiques de n-achr pour le traitement des troubles psychotiques et neurodegeneratifs.

Also Published As

Publication number	Publication date
CA2002182C (fr)	2000-06-13

Similar Documents

Publication	Publication Date	Title
CA2001572A1 (fr)	1990-04-26	Composes pour le traitement des symptomes de sevrage du tabac
MY106272A (en)	1995-04-29	Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
DE69202207D1 (de)	1995-06-01	Verfahren zur Herstellung von 1-Chlor-1,1,3,3,3-Pentafluorpropan und von 1,1,1,3,3,3-Hexafluorpropan.
IL96458A0 (en)	1991-08-16	Isoxazolines,their preparation,and their use as plantprotecting agents
AU2566892A (en)	1993-04-27	Composition suitable for forming into shaped articles, process for preparing the composition, process for preparing shaped articles using the composition, and shaped articles so-formed
IE891798L (en)	1989-12-02	Novel ó-glucosidase inhibitors
ZA899725B (en)	1990-09-26	N-aryl-azetidinones,their preparation process and their use as elastage inhibitors
DE3856295D1 (de)	1999-02-18	Behandlung des prämenstruellen oder späten lutealsphase-syndroms
IL110204A0 (en)	1995-01-24	Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
HUT47103A (en)	1989-01-30	Process for producing 1,4-benzoxazine derivatives and pharmaceutical compositions comprising the same
CA2017851A1 (fr)	1990-11-30	Particules biodegradables micronisees; methode de preparation et utilisation
RU93058535A (ru)	1996-09-20	Таблетка, содержащая гидрохлорид колестипола и способ ее получения
HU9303638D0 (en)	1994-04-28	Reagent mixtures composition for blood-test, process for production of the composition, and process for examination blood-samples of glucose-content
PT66089A (en)	1977-02-01	Process for preparing 1,2-benzisothiazolin-3-ona with anti-thrombotic effect,application of same for the preparation of pharmaceutical compositions with anti-thrombic effect and application of these pharmaceutical compositions for the treatment of thrombosis
EP0264744A3 (en)	1988-10-19	Process for the preparation of 4,4'-diaminodiphenylmethane and its derivatives.
IL99500A0 (en)	1992-08-18	Naphthalene compounds,processes for the preparation thereof and pharmaceutical compositions containing the same
ZA925892B (en)	1993-07-28	Organic nitrates, processes for their preparation and their use in the treatment of cardiovascular diseases.
EP0318233A3 (fr)	1990-07-11	Inhibiteurs d'assimilation de sérotonine et de norépinéphrine
LTIP911A (en)	1995-03-27	Indenoindole compounds i,process for preparing thereof,pharmaceutical compositions containing this compounds,and their use
AU4926190A (en)	1990-08-16	2,3,23-trihydroxy-urs-12-ene and its derivatives, processes for their preparation and their use
HU9201799D0 (en)	1992-08-28	New 2-amino-5-ciano-1,4-dihydropiridine-derivatives, process for their use and their use as medicaments
GB2235198B (en)	1993-06-02	Novel aminopropanol derivatives,process for their preparation and pharmaceutical compositions comprising the same
ZA898775B (en)	1990-08-29	Cyclopropyl-substituted azolylmethylcarbinols,processes for their preparation and their use as medicaments
EP0386920A3 (fr)	1991-11-27	Dérivés d'hydroxy-2-thiénylox-3-propylamine
HUT53773A (en)	1990-12-28	Antidotums containing substituted 1,8-naphtiridine derivatives as aktive components and process for producing the active components

Legal Events

Date	Code	Title	Description
1996-10-22	EEER	Examination request
2007-11-05	MKLA	Lapsed